RecruitingPhase 3NCT06900543

Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere

Studying Pediatric hepatocellular carcinoma

Last synced from ClinicalTrials.gov May 18, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Chengdu New Radiomedicine Technology Co. LTD.
Principal Investigator: Gaojun Teng
Zhongda Hospital
Intervention: NRT6003 Injection(drug)
Enrollment: 108 enrolled
Eligibility: 18 years · All sexes
Timeline: 2025 – 2027

Study locations (11)

Fujian Cancer Hospital, Fuzhou, Fujian, China
Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian, China
The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
Henan Cancer Hospital, Zhengzhou, Henan, China
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China
Zhongda Hospital Southeast University, Nanjing, Jiangsu, China
The First Hospital of China Medical University, Shenyang, Liaoning, China
West China Hospital, Chengdu, Sichuan, China
Tianjin Cancer Hospital Airport Hospital, Tianjin, Tianjin Municipality, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06900543 on ClinicalTrials.gov

Other trials for Pediatric hepatocellular carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Pediatric hepatocellular carcinoma →

← Back to all trials